lurasidone + lithium

**lurasidone + lithium** is a combination therapy of two pharmaceutical agents—lurasidone, an atypical antipsychotic, and lithium, a classic mood stabilizer and antimanic agent. This combination is primarily used for the management of depressive episodes associated with bipolar I disorder (bipolar depression). Lurasidone acts mainly as an antagonist at dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors, as well as a partial agonist at serotonin 5-HT1A receptors; it has negligible affinity for histamine H1 and muscarinic receptors. Lithium's therapeutic action is thought to involve modulation of neurotransmitter release (affecting serotonin, dopamine, and norepinephrine), signaling pathways, and second messenger systems. The combination is FDA-approved, based on evidence that adjunctive therapy with lurasidone and lithium is more effective for bipolar depression than placebo or monotherapy, with a relatively favorable safety profile[1][2][4][5][6].